Structure - Activity relationship studies of chalcone leading to 3-hydroxy-4,3′,4′,5′-tetramethoxychalcone and its analogues as potent nuclear factor κB inhibitors and their anticancer activities

Journal of Medicinal Chemistry

Volumn 52, Issue 22, 2009, Pages 7228-7235

  Srinivasan, Balasubramanian ^a   Johnson, Thomas E ^a   Lad, Rahul ^a   Xing, Chengguo ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 HYDROXY 4,6 DIMETHOXYPHENYL) 3 (4 METHOXY 3 METHYLPHENYL)PROP 2 EN 1 ONE; 1 (2 HYDROXY 4,6 DIMETHOXYPHENYL) 3 M TOLYLPROP 2 EN 1 ONE; 1 (2 HYDROXY 4,6 DIMETHOXYPHENYL) 3 O TOLYLPROP 2 EN 1 ONE; 1 (3,4 DIMETHOXYPHENYL) 3 (3 HYDROXY 4 METHOXYPHENYL)PROP 2 EN 1 ONE; 1 (4 HYDROXY 3,5 DIMETHOXYPHENYL) 3 (3 HYDROXY 4 METHOXYPHENYL)PROP 2 EN 1 ONE; 3 (3 HYDROXY 4 METHOXYPHENYL) 1 (3,4,5 TRIMETHOXYPHENYL)PROPAN 1 ONE; 3 [3 (2 AMINOETHOXY) 4 METHOXYPHENYL] 1 (3,4,5 TRIMETHOXYPHENYL)PROP 2 EN 1 ONE; 3 [3 (2 HYDROXYETHOXY) 4 METHOXYPHENYL] 1 (3,4,5 TRIMETHOXYPHENYL)PROP 2 EN 1 ONE; 3 HYDROXY 4,3',4',5' TETRAMETHOXYCHALCONE; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; CHALCONE DERIVATIVE; I KAPPA B; LEAD; UNCLASSIFIED DRUG;

ALDOL REACTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; DRUG SYNTHESIS; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN CELL; LUNG CANCER; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CHALCONE; CHALCONES; FEMALE; GENES, REPORTER; HUMANS; I-KAPPA B KINASE; INHIBITORY CONCENTRATION 50; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; LUCIFERASES; LUNG NEOPLASMS; MICE; MICE, NUDE; NF-KAPPA B; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70949087763     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm901278z     Document Type: Article

References (56)

1. Wattenberg, L. W.; Coccia, J. B.; Galbraith, A. R. Inhibition of carcinogen-induced pulmonary and mammary carcinogenesis by chalcone administered subsequent to carcinogen exposure. Cancer Lett. 1994, 83, 165-169.
2. Ducki, S.; Forrest, R.; Hadfield, J. A.; Kendall, A.; Lawrence, N. J.; McGown, A. T.; Rennison, D. Potent antimitotic and cell growth inhibitory properties of substituted chalcones. Bioorg. Med. Chem. Lett. 1998, 8, 1051-1056.
3. Baba, M.; Asano, R.; Takigami, I.; Takahashi, T.; Ohmura, M.; Okada, Y.; Sugimoto, H.; Arika, T.; Nishino, H.; Okuyama, T. Studies on cancer chemoprevention by traditional folk medicines XXV. Inhibitory effect of isoliquiritigenin on azoxymethane-induced murine colon aberrant crypt focus formation and carcinogenesis. Biol. Pharm. Bull. 2002, 25, 247-250.
4. Kapadia, G. J.; Azuine, M. A.; Tokuda, H.; Hang, E.; Mukainaka, T.; Nishino, H.; Sridhar, R. Inhibitory effect of herbal remedies on 12-o-tetradecanoylphorbol-13-acetate-promoted Epstein-Barr virus early antigen activation*1. Pharm. Res. 2002, 45, 213-220.
5. Kinghorn, A. D.; Su, B. N.; Jang, D. S.; Chang, L. C.; Lee, D.; Gu, J. Q.; Carcache-Blanco, E. J.; Pawlus, A. D.; Lee, S. K.; Park, E. J.; Cuendet, M.; Gills, J. J.; Bhat, K.; Park, H. S.; Mata-Greenwood, E.; Song, L. L.; Jang, M.; Pezzuto, J. M. Natural inhibitors of carcinogenesis. Planta Med. 2004, 70, 691-705.
6. Rao, Y. K.; Fang, S. H.; Tzeng, Y. M. Differential effects of synthesized 2′-oxygenated chalcone derivatives: modulation of human cell cycle phase distribution. Bioorg. Med. Chem. 2004, 12, 2679-2686.
7. Takahashi, T.; Takasuka, N.; Iigo, M.; Baba, M.; Nishino, H.; Tsuda, H.; Okuyama, T. Isoliquiritigenin, a flavonoid from licorice, reduces prostaglandin E2 and nitric oxide, causes apoptosis, and suppresses aberrant crypt foci development. Cancer Sci. 2004, 95, 448-453.
8. Ye, C. L.; Liu, J. W.; Wei, D. Z.; Lu, Y. H.; Qian, F. In vivo antitumor activity by 2′,4′-dihydroxy-6′-methoxy-3′,5′- dimethylchalcone in a solid human carcinoma xenograft model. Cancer Chemother. Pharmacol. 2005, 55, 447-452.
9. Zi, X.; Simoneau, A. R. Flavokawain A, a novel chalcone from kava extract, induces apoptosis in bladder cancer cells by involvement of Bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in mice. Cancer Res. 2005, 65, 3479-3486.
10. Achanta, G.; Modzelewska, A.; Feng, L.; Khan, S. R.; Huang, P. A boronic-chalcone derivative exhibits potent anticancer activity through inhibition of the proteasome. Mol. Pharmacol. 2006, 70, 426-433.
11. Hsu, Y. L.; Kuo, P. L.; Tzeng, W. S.; Lin, C. C. Chalcone inhibits the proliferation of human breast cancer cell by blocking cell cycle progression and inducing apoptosis. Food Chem. Toxicol. 2006, 44, 704-713.
12. Kim, D. Y.; Kim, K. H.; Kim, N. D.; Lee, K. Y.; Han, C. K.; Yoon, J. H.; Moon, S. K.; Lee, S. S.; Seong, B. L. Design and biological evaluation of novel tubulin inhibitors as antimitotic agents using a pharmacophore binding model with tubulin. J. Med. Chem. 2006, 49, 5664-5670.
13. Modzelewska, A.; Pettit, C.; Achanta, G.; Davidson, N. E.; Huang, P.; Khan, S. R. Anticancer activities of novel chalcone and bis-chalcone derivatives. Bioorg. Med. Chem. 2006, 14, 3491-3495.
14. Shen, K. H.; Chang, J. K.; Hsu, Y. L.; Kuo, P. L. Chalcone arrests cell cycle progression and induces apoptosis through induction of mitochondrial pathway and inhibition of nuclear factor kappa B signalling in human bladder cancer cells. Basic Clin. Pharmacol. Toxicol. 2007, 101, 254-261.
15. Wattenberg, L. W. Chalcones, myo-inositol and other novel inhibitors of pulmonary carcinogenesis. J. Cell Biochem., Suppl. 1995, 22, 162-168.
16. Baba, M.; Asano, R.; Takigami, I.; Takahashi, T.; Ohmura, M.; Okada, Y.; Sugimoto, H.; Arika, T.; Nishino, Y.; Okuyama, T. Studies on cancer chemoprevention by traditional folk medicines. XXV. Inhibitory effect of isoliquiritigenin on azoxymethane-induced murine colon aberrant crypt focus formation and carcinogenesis. Biol. Pharm. Bull. 2002, 25, 247-250.
17. Kanazawa, M.; Satomi, Y.; Mizutani, Y.; Ukimura, O.; Kawauchi, A.; Sakai, T.; Baba, M.; Okuyama, T.; Nishino, H.; Miki, T. Isoliquiritigenin inhibits the growth of prostate cancer. Eur. Urol. 2003, 43, 580-586.
18. Yamazaki, S.; Morita, T.; Endo, H.; Hamamoto, T.; Baba, M.; Joichi, Y.; Kaneko, S.; Okada, Y.; Okuyama, T.; Nishino, H.; Tokue, A. Isoliquiritigenin suppresses pulmonary metastasis of mouse renal cell carcinoma. Cancer Lett. 2002, 183, 23-30. (Pubitemid 34607348)
19. Israf, D. A.; Khaizurin, T. A.; Syahida, A.; Lajis, N. H.; Khozirah, S. Cardamonin inhibits COX and iNOS expression via inhibition of p65NF-kappaB nuclear translocation and Ikappa-B phosphorylation in RAW 264.7 macrophage cells. Mol. Immunol. 2007, 44, 673-679.
20. Phillpotts, R. J.; Higgins, P. G.; Willman, J. S.; Tyrrell, D. A.; Lenox-Smith, I. Evaluation of the antirhinovirus chalcone Ro 09-0415 given orally to volunteers. J. Antimicrob. Chemother. 1984, 14, 403-409.
21. Peyrot, V.; Leynadier, D.; Sarrazin, M.; Briand, C.; Rodriquez, A.; Nieto, J. M.; Andreu, J. M. Interaction of tubulin and cellular microtubules with the new antitumor drug MDL 27048. A powerful and reversible microtubule inhibitor. J. Biol. Chem. 1989, 264, 21296-21301.
22. Edwards, M. L.; Stemerick, D. M.; Sunkara, P. S. Chalcones: a new class of antimitotic agents. J. Med. Chem. 1990, 33, 1948-1954.
23. Lawrence, N. J.; McGown, A. T.; Ducki, S.; Hadfield, J. A. The interaction of chalcones with tubulin. Anti-Cancer Drug Des. 2000, 15, 135-141.
24. Bhat, B. A.; Dhar, K. L.; Puri, S. C.; Saxena, A. K.; Shanmugavel, M.; Qazi, G. N. Synthesis and biological evaluation of chalcones and their derived pyrazoles as potential cytotoxic agents. Bioorg. Med. Chem. Lett. 2005, 15, 3177-3180.
25. Lawrence, N. J.; Patterson, R. P.; Ooi, L. L.; Cook, D.; Ducki, S. Effects of alpha-substitutions on structure and biological activity of anticancer chalcones. Bioorg. Med. Chem. Lett. 2006, 16, 5844-5848.
26. Miglarese, M. R.; Carlson, R. O. Development of new cancer therapeutic agents targeting mitosis. Expert Opin. Invest. Drugs 2006, 15, 1411-1425
27. Rowinsky, E. K.; Calvo, E. Novel agents that target tublin and related elements. Semin. Oncol. 2006, 33, 421-435.
28. Liu, X.; Go, M. L. Antiproliferative properties of piperidinylchalcones. Bioorg. Med. Chem. 2006, 14, 153-163.
29. Lee, Y. S.; Lim, S. S.; Shin, K. H.; Kim, Y. S.; Ohuchi, K.; Jung, S. H. Anti-angiogenic and anti-tumor activities of 2′-hydroxy-4′- methoxychalcone. Biol. Pharm. Bull. 2006, 29, 1028-1031.
30. Luo, Y.; Eggler, A. L.; Liu, D.; Liu, G.; Mesecar, A. D.; van Breemen, R. B. Sites of alkylation of human Keap1 by natural chemoprevention agents. J. Am. Soc. Mass. Spectrom. 2007, 18, 2226-2232.
31. Coussens, L. M.; Werb, Z. Inflammation and cancer. Nature 2002, 420, 860-867.
32. Maeda, S.; Omata, M. Inflammation and cancer: role of nuclear factor-kappaB activation. Cancer Sci. 2008, 99, 836-842.
33. Lu, H.; Ouyang, W.; Huang, C. Inflammation, a key event in cancer development. Mol. Cancer Res. 2006, 4, 221-233.
34. Federico, A.; Morgillo, F.; Tuccillo, C.; Ciardiello, F.; Loguercio, C. Chronic inflammation and oxidative stress in human carcinogenesis. Int. J. Cancer. 2007, 121, 2381-2386.
35. Zhang, Z.; Rigas, B. NF-kappaB, inflammation and pancreatic carcinogenesis: NF-kappaB as a chemoprevention target. Int. J. Oncol. 2006, 29, 185-192.
36. Pikarsky, E.; Porat, R. M.; Stein, I.; Abramovitch, R.; Amit, S.; Kasem, S.; Gutkovich-Pyest, E.; Urieli-Shoval, S.; Galun, E.; Ben-Neriah, Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004, 431, 461-466. (Pubitemid 39329586)
37. Karin, M. NF-kappaB and cancer: mechanisms and targets. Mol. Carcinog. 2006, 45, 355-361.
38. Funakoshi-Tago, M.; Tanabe, S.; Tago, K.; Itoh, H.; Mashino, T.; Sonoda, Y.; Kasahara, T. Licochalcone A potently inhibits TNF-{alpha}-induced NF-{kappa}B activation through the direct inhibition of IKK activation. Mol. Pharmacol. 2009, DOI: 10.1124/mol.109.057448.
39. Harikumar, K. B.; Kunnumakkara, A. B.; Ahn, K. S.; Anand, P.; Krishnan, S.; Guha, S.; Aggarwal, B. B. Modification of the cysteine residues in IkappaBalpha kinase and NF-kappaB (p65) by xanthohumol leads to suppression of NF-kappaB-regulated gene products and potentiation of apoptosis in leukemia cells. Blood 2009, 113, 2003-2013.
40. Kim, J. Y.; Park, S. J.; Yun, K. J.; Cho, Y. W.; Park, H. J.; Lee, K. T. Isoliquiritigenin isolated from the roots of Glycyrrhiza uralensis inhibits LPS-induced iNOS and COX-2 expression via the attenuation of NF-kappaB in RAW 264.7 macrophages. Eur. J. Pharmacol. 2008, 584, 175-184.
41. Shen, K. H.; Chang, J. K.; Hsu, Y. L.; Kuo, P. L. Chalcone arrests cell cycle progression and induces apoptosis through induction of mitochondrial pathway and inhibition of nuclear factor kappa B signalling in human bladder cancer cells. Basic Clin. Pharmacol. Toxicol. 2007, 101, 254-261.
42. Pandey, M. K.; Sandur, S. K.; Sung, B.; Sethi, G.; Kunnumakkara, A. B.; Aggarwal, B. B. Butein, a tetrahydroxychalcone, inhibits nuclear factor (NF)-kappaB and NF-kappaB-regulated gene expression through direct inhibition of IkappaBalpha kinase beta on cysteine 179 residue. J. Biol. Chem. 2007, 282, 17340-17350.
43. Folmer, F.; Blasius, R.; Morceau, F.; Tabudravu, J.; Dicato, M.; Jaspars, M.; Diederich, M. Inhibition of TNFalpha-induced activation of nuclear factor kappaB by kava (Piper methysticum) derivatives. Biochem. Pharmacol. 2006, 71, 1206-1218.
44. Israf, D. A.; Khaizurin, T. A.; Syahida, A.; Lajis, N. H.; Khozirah, S. Cardamonin inhibits COX and iNOS expression via inhibition of p65NF-kappaB nuclear translocation and Ikappa-B phosphorylation in RAW 264.7 macrophage cells. Mol. Immunol. 2007, 44, 673-679.
45. Madan, B.; Batra, S.; Ghosh, B. 2′-Hydroxychalcone inhibits nuclear factor-kappaB and blocks tumor necrosis factor-alpha- and lipopolysaccharide- induced adhesion of neutrophils to human umbilical vein endothelial cells. Mol. Pharmacol. 2000, 58, 526-534.
46. Lorenzo, P.; Alvarez, R.; Ortiz, M. A.; Alvarez, S.; Piedrafita, F. J.; de Lera, A. R. Inhibition of IkappaB kinase-beta and anticancer activities of novel chalcone adamantyl arotinoids. J. Med. Chem. 2008, 51, 5431-5440.
47. Shishodia, S.; Amin, H. M.; Lai, R.; Aggarwal, B. B. Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem. Pharmacol. 2005, 70, 700-713.
48. Ban, H. S.; Suzuki, K.; Lim, S. S.; Jung, S. H.; Lee, S.; Ji, J.; Lee, H. S.; Lee, Y. S.; Shin, K. H.; Ohuchi, K. Inhibition of lipopolysaccharide- induced expression of inducible nitric oxide synthase and tumor necrosis factor-alpha by 2′-hydroxychalcone derivatives in RAW 264.7 cells. Biochem. Pharmacol. 2004, 67, 1549-1557.
49. Kumar, S.; Sharma, A.; Madan, B.; Singhal, V.; Ghosh, B. Isoliquiritigenin inhibits IkappaB kinase activity and ROS generation to block TNF-alpha induced expression of cell adhesion molecules on human endothelial cells. Biochem. Pharmacol. 2007, 73, 1602-1612.
50. Vogel, S.; Ohmayer, S.; Brunner, G.; Heilmann, J. Natural and non-natural prenylated chalcones: synthesis, cytotoxicity and antioxidative activity. Bioorg. Med. Chem. 2008, 16, 4286-4293.
51. Khupse, R. S.; Erhardt, P. W. Total synthesis of xanthohumol. J. Nat. Prod. 2007, 70, 1507-1509.
52. Tsang, K. Y.; Sinha, S.; Liu, X.; Bhat, S.; Chandraratna, R. A. Preparation of Disubstituted Chalcone Oximes as Selective Agonists of RAR-r Retinoid Receptors. U.S. Pat. Appl. Publ. US 2005148590, 2005.
53. Schmid, J. A.; Birbach, A. IkappaB kinase beta (IKKbeta/IKK2/IKBKB), a key molecule in signaling to the transcription factor NF-kappaB. Cytokine Growth Factor Rev. 2008, 19, 157-165.
54. Häcker, H.; Karin, M. Regulation and function of IKK and IKK-related kinases. Sci. STKE 2006, 357, 1-19.
55. Ballaz, S.; Mulshine, J. L. The potential contributions of chronic inflammation to lung carcinogenesis. Clin. Lung Cancer 2003, 5, 46-62. (Pubitemid 36974741)
56. Doshi, J. M.; Tian, D.; Xing, C. Ethyl-2-amino-6-bromo-4-(1-cyano-2- ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), a prototype small-molecule antagonist against anti-apoptotic Bcl-2 proteins, decomposes to generate reactive oxygen species (ROS) that induce apoptosis. Mol. Pharmaceutics 2007, 4, 919-928.